Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 18/20 | 0.47 |
| ▸ | ITGA2B | P08514 | 18/20 | 0.47 |
| ▸ | ITGAV | P06756 | 2/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12160456 | 1.00 | ITGB3 (0.47) | ITGB3ITGA2BITGAVCHRM2SLC6A4 | |
| SCHEMBL12106892 | 0.91 | ITGB3 (0.48) | ITGB3ITGA2BITGAVCHRM2SLC6A4 | |
| SCHEMBL12160457 | 0.89 | GPR119 (0.47) | ITGB3ITGA2B | |
| SCHEMBL12160406 | 0.89 | GPR119 (0.47) | ITGB3ITGA2B | |
| SCHEMBL12160423 | 0.89 | GPR119 (0.47) | ITGB3ITGA2B | |
| SCHEMBL13534979 | 0.87 | ITGB3 (0.45) | ITGB3ITGA2BITGAVCHRM2SLC6A4 | |
| SCHEMBL12160488 | 0.86 | ITGB3 (0.53) | ITGB3ITGA2BITGAVCHRM2SLC6A4 | |
| SCHEMBL1841876 | 0.85 | GPR119 (0.42) | — | |
| SCHEMBL12160436 | 0.85 | ITGB3 (0.47) | ITGB3ITGA2BITGAVCHRM2SLC6A4 | |
| SCHEMBL12160383 | 0.85 | ACACB (0.35) | ITGB3ITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110269734-A1 | PIPERIDINYL GPCR AGONISTS | PROSIDION LIMITED (GB) | 2011-11-03 | — | — | US | disclosed |
| EP-2383270-A1 | Piperidine GPCR agonists | Prosidion Limited (GB) | 2011-11-02 | — | — | EP | disclosed |
| WO-2010004348-A1 | HETEROCYCLIC GPCR AGONISTS | PROSIDION LIMITED (GB) | 2010-01-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269734-A1 | PIPERIDINYL GPCR AGONISTS | GPR119, GPR27, GLP1R | ITGB3 3442/4885ITGA2B 3353/4885ITGAV 3335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.